Carrie Dial, in Fairway, KS - Marriage & Family Therapist

Carrie Dial, is a Marriage & Family Therapist based in Fairway, Kansas. Carrie Dial is licensed to practice in Kansas (license number T-LMFT 2419) and her current practice location is 5301 Norwood St, Fairway, Kansas. She can be reached at her office (for appointments etc.) via phone at (816) 678-6728.

NPI number for Carrie Dial is 1184975328 and her current mailing address is 119 Barberry Ln, Raymore, Missouri. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1184975328.

Contact Information

	Carrie Dial,
	5301 Norwood St, Fairway, KS 66205-2647
	(816) 678-6728
	Not Available

Healthcare Provider's Profile

Full Name	Carrie Dial
Gender	Female
Speciality	Marriage & Family Therapist
Location	5301 Norwood St, Fairway, Kansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1184975328
Provider Enumeration Date: 09/27/2012
Last Update Date: 09/27/2012

Medical Identifiers

Medical identifiers for Carrie Dial such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1184975328	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	T-LMFT 2419 (Kansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Carrie Dial is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Carrie Dial, 119 Barberry Ln, Raymore, MO 64083-8632 Ph: (816) 678-6728	Carrie Dial, 5301 Norwood St, Fairway, KS 66205-2647 Ph: (816) 678-6728

News Archive

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

Hyaluronic hydrogels provide scaffolding for growth of bone cells

Hyaluronic hydrogels developed by Carnegie Mellon University researchers may provide a suitable scaffolding to enable bone regeneration.

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.

Carrie Dial, - Couples Therapy in Fairway, KS